Creating a rabbit model to study epilepsy and related heart conditions.
Development of a Genetic Rabbit Model of Kcnh2-Mediated Epilepsy, SUDEP, & Long QT Syndrome Type 2
This study is creating special rabbits with genetic changes to help us learn more about epilepsy and related heart problems, so we can find better and safer treatments for people who have seizures and are at risk for sudden heart issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project ID | NIH-10907815 on NIH RePORTER |
What this research studies
This research focuses on developing a genetically modified rabbit model to better understand Kcnh2-mediated epilepsy, Sudden Unexpected Death in Epilepsy (SUDEP), and Long QT Syndrome Type 2 (LQT2). By using CRISPR technology, researchers aim to create rabbits with specific genetic mutations that mimic these conditions, allowing for more accurate studies of their effects on both the brain and heart. This model will help identify safe and effective anti-seizure medications for patients who are at risk of seizures and cardiac issues. The goal is to bridge the gap between current animal models and human conditions to improve treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Kcnh2-mediated epilepsy or Long QT Syndrome Type 2.
Not a fit: Patients without genetic variants linked to Kcnh2 or those who do not have epilepsy or Long QT Syndrome Type 2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective treatments for patients with epilepsy and related cardiac conditions.
How similar studies have performed: While this approach is innovative, previous research has shown success in using animal models to study epilepsy and cardiac conditions, but this specific model is novel.
Where this research is happening
Syracuse, United States
- Upstate Medical University — Syracuse, United States (Active)
Researchers
- Principal investigator: Auerbach, David Scott — Upstate Medical University
- Study coordinator: Auerbach, David Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.